Clinical Trials · NCT01938235
Exenatide for Myocardial Protection During Reperfusion Study
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- University Health Network, Toronto
- Enrollment
- 198
- Start date
- Feb 2014
- Locations
- 10 sites, Canada
- Primary endpoint
- Ratio of final infarct size at 3 months over area at risk at 72 hours post randomization (using cMRI)